Bladder & Urothelial Cancer Excellence Forum

Bladder & Urothelial Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Siamak Daneshmand, MD, Norris Comprehensive Cancer Center at USC

Videos

Erdafitinib for Patients With Intermediate-Risk Non-Muscle Invasive Bladder Cancer

03/02/2023

At the 2023 ASCO GU Cancers Symposium, Siamak Daneshmand, MD, reported interim analysis results from Cohort 3 of the phase 2 THOR-2 trial.

At the 2023 ASCO GU Cancers...

03/02/2023

Oncology

James Catto, MB, ChB, PhD, University of Sheffield

Videos

Erdafitinib for Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

03/02/2023

At the 2023 ASCO GU Cancers Symposium, James Catto, MB, ChB, PhD, discusses results from Cohort 2 of a phase 2 trial evaluating erdafitinib among patients with bacillus Calmette-Guérin (BCG)-unresponsive, high risk, non-muscle-invasive...

At the 2023 ASCO GU Cancers...

03/02/2023

Oncology

Daniel Geynisman, MD, Fox Chase Cancer Center

Videos

Risk-Adapted Approach for Muscle-Invasive Bladder Cancer Requires Further Refinement

03/01/2023

At the 2023 ASCO GU Cancers Symposium, Daniel Geynisman, MD, shares results of a trial examining a risk-adapted approach to treatment for patients with muscle-invasive bladder cancer.

At the 2023 ASCO GU Cancers...

03/01/2023

Oncology

Srikala Sridhar, MD, Princess Margaret Cancer Center

Videos

Avelumab Maintenance for Urothelial Carcinoma by First-Line Chemotherapy Regimen

02/28/2023

At the 2023 ASCO GU Cancers Symposium, Srikala Sridhar, MD, shares results and insights from the long-term follow-up of the JAVELIN Bladder 001 trial.

At the 2023 ASCO GU Cancers...

02/28/2023

Oncology

Andrew Katims, MD, Memorial Sloan Kettering Cancer Center

Videos

Assessing the MSK-ACCESS ctDNA Assay in Node-Positive Muscle-Invasive Bladder Cancer

02/21/2023

At the 2023 ASCO GU Cancers Symposium, Andrew Katims, MD, presents results from an assessment of a ctDNA assay in node-positive muscle-invasive bladder cancer.

At the 2023 ASCO GU Cancers...

02/21/2023

Oncology

Kyle Rose, MD, Moffitt Cancer Center & Research Institute

Videos

Urinary Tumor DNA for Minimal Residual Disease Detection at Repeat TURBT in Non-Muscle-Invasive Bladder Cancer

02/21/2023

At the 2023 ASCO GU Cancers Symposium, Kyle Rose, MD, presents results from a prospective study investigating urinary tumor DNA as a surrogate for minimal residual disease among patients with NMIBC undergoing repeat TURBT.

At the 2023 ASCO GU Cancers...

02/21/2023

Oncology

Aristotelis Bamias, MD, University of Athens

Videos

Atezolizumab Monotherapy vs Chemotherapy for Patients with Metastatic Urothelial Carcinoma

02/17/2023

At the 2023 ASCO Genitourinary Cancer Symposium, Aristotelis Bamias, MD, discusses overall survival results from the IMvigor130 study, evaluating atezolizumab monotherapy and platinum/gemcitabine chemotherapy among previously untreated...

At the 2023 ASCO Genitourinary...

02/17/2023

Oncology

Peter O'Donnell, MD, University of Chicago

Videos

Efficacy and Safety of Pembrolizumab for Metastatic Urothelial Carcinoma

01/17/2023

Peter O’Donnell, MD, discusses an analysis from from the KEYNOTE-045 and KEYNOTE-052 trials, showing continued efficacy and safety of pembrolizumab for patients with metastatic urothelial carcinoma after 5 years of follow-up.

Peter O’Donnell, MD, discusses...

01/17/2023

Oncology

Quiz

Quiz: Impact of Chemotherapy Choice on Later Immune Checkpoint Inhibitors for Urothelial Carcinoma

12/01/2022

How did first-line cisplatin versus carboplatin impact the survival of patients receiving immune checkpoint inhibitors in the second-line setting?

How did first-line cisplatin...

12/01/2022

Oncology

Andrea Necchi, MD, San Raffaele Hospital

Videos

3-Year Efficacy of Neoadjuvant Pembrolizumab Before Radical Cystectomy For Muscle-Invasive Bladder Cancer

11/03/2022

Andrea Necchi, MD, shares follow-up data from the phase 2 PURE-01 trial, confirming the sustained efficacy of neoadjuvant pembrolizumab before radical cystectomy in patients with muscle-invasive urothelial bladder cancer.

Andrea Necchi, MD, shares...

11/03/2022

Oncology

Recent News

News

Pembrolizumab Yields Meaningful Benefit in Advanced Urothelial Cancer

07/27/2020

Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.

Pembrolizumab was active in...

07/27/2020

Oncology

News

Switch Maintenance Pembrolizumab Improves Response, PFS in Metastatic Urothelial Cancer

05/01/2020

Switch maintenance pembrolizumab led to improved PFS and ORRs in patients with metastatic urothelial cancer, according to results from a phase 2 study.

Switch maintenance pembrolizumab...

05/01/2020

Oncology

News

Enfortumab Vedotin Monotherapy Yields Durable Responses in Metastatic Urothelial Cancer

02/26/2020

Enfortumab vedotin monotherapy has demonstrated meaningful and durable responses in patients with metastatic urothelial cancer.

Enfortumab vedotin monotherapy...

02/26/2020

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology